Propanc Biopharma, Inc.
PPCB· Nasdaq
Filed Nov 12, 2021 · 10-Q · 43 days after period end · 0001493152-21-028221
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Net Income | -$490.66K | -$425.55K | -$1.49M | -$2.12M |
| EPS Diluted | -$0.02 | -$0.71 | -$1.41 | -$10.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end